29:33

Good Identification Practices in Non-Targeted Screening Analyses

53:05

USP 665 and 1665 Extractables for Components in Pharmaceutical and Biopharmaceutical Manufacturing

27:14

Viral Clearance: A WuXi Advanced Therapies Perspective

30:49

Viral Clearance: Removal of Viral Contamination in Biopharmaceutical Manufacturing

1:28:07

Regulatory tools for assessing the skin sensitization potential of chemicals and a case study

1:00:25

Virology Lectures 2024 #1: What is a virus?

26:11

Challenge for Industry with new USP (665) / (1665)

31:30

Current methods and factors to take into account for viral clearance in cell and gene therapy